Thiazolidinediones

Thiazolidinediones has been studied in 120 papers since 2007: 1 trial and 43 observational studies in people, 2 in animals, 72 reviews; 57 in the past year. The newest paper, Nov 18, 2026: “Comparative Risk of Incident Autoimmune Diseases by First Add-on Antidiabetic Drug Class After Metformin: A Population-Based Active-Comparator, New-User Cohort Study”.

Intervention

120 papers study it33 findingsUpdated

MeSH

15 new papers in 30 daysSee all 119 papers on thiazolidinediones

At a glance

Independent labs found the same change in people. 23 independent labs in 10 countries; 2 trials, none about aging, 1 with no results posted.

“Thiazolidinedione use (hazard ratio [HR] 1.22; 95% CI, 1.02-1.46) and insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”
Predictors of Fracture in Middle-Aged and Older Adults With Type 2 Diabetes and Overweight or ObesityThe Journal of clinical endocrinology and metabolism2024doi:10.1210/clinem/dgae623

1 of its findings points the other way.

Humans: replicated by independent labs. Worms or flies: a single group. Cells and mice: nothing yet.
  • 23 independent labs in 10 countries
  • 1 finding against
  • 2 trials, none about aging, 1 with no results posted
  • Funders: National Institutes of Health and others
  • 4 of 25 findings with company ties
  • Human trial1
  • Humans43
  • Model organisms2
  • In silico2

What did studies of thiazolidinediones find?

9

Studies of thiazolidinediones measured 9 outcomes; the most studied is inflammation (3 studies).

Inflammation

downin reviews2downin humans1

3 studies
  1. Thiazolidinediones are linked with inflammation in humans (type 2 diabetes mellitus).

    “SGLT-2 inhibitors and TZDs demonstrated stronger and more integrated anti-inflammatory networks, whereas Biguanidines and DPP-4 inhibitors exhibited moderate coherence.”

    Humanstype 2 diabetes mellitusone yearn = 13,425

    Comparative Longitudinal Evaluation of Systemic Inflammatory Markers in Type 2 Diabetes Treated with Four Oral Antidiabetic Drug Classes

    Journal of clinical medicine

  2. Thiazolidinediones decrease inflammation.

    “TZDs exert anti-inflammatory effects that may reduce obesity-related cancer risks.”

    Review

    Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review

    Molecular aspects of medicine

  3. Thiazolidinediones decrease inflammation (preclinical models of Alzheimer's disease).

    “TZDs ameliorated neuroinflammation and ferroptosis in preclinical models of AD.”

    Reviewpreclinical models of Alzheimer's disease

    Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis

    Journal of Alzheimer's disease : JAD

More on Inflammation

Dementia

no changein humans1

1 study
  1. Thiazolidinediones were not clearly linked with dementia in humans.

    “Dementia risk was similar for TZDs, DPP-4inhibitors and SUs”

    Humanscompared with dipeptidyl peptidase-4 inhibitors and sulfonylureas, in adults with type 2 diabetes on metforminup to 5 years

    Effect of thiazolidinediones compared to other antidiabetic medications on incident dementia in people with type 2 diabetes: A target trial emulation study

    medRxivPreprint

More on Dementia

Vascular dementia

no changein humans1

1 study
  1. Thiazolidinediones were not clearly linked with vascular dementia in humans (aHR 0.89 (95% CI 0.36-2.23)).

    “TZD were associated with a similar risk of vascular dementia compared with DPP-4 inhibitors (aHR 0.89;95% CI 0.36-2.23)”

    Humanscompared with dipeptidyl peptidase-4 inhibitors, in adults with type 2 diabetes on metforminup to 5 years

    Effect of thiazolidinediones compared to other antidiabetic medications on incident dementia in people with type 2 diabetes: A target trial emulation study

    medRxivPreprint

More on Vascular dementia

Breast cancer-related lymphedema

no changein humans1

1 study
  1. Thiazolidinediones showed no clear effect on breast cancer-related lymphedema in humans (stage I-III breast cancer).

    “thiazolidinediones, anti-hypertensives, and non-steroidal anti-inflammatory drugs (NSAIDs) had no effect on BCRL incidence”

    Reviewstage I-III breast cancer

    Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review

    Frontiers in oncology

More on Breast cancer-related lymphedema

Bone mineral density

downin humans1

1 study
  1. Thiazolidinediones are linked with lower bone mineral density in men with type 2 diabetes.

    “Among men with type 2 diabetes, TZD, insulin, and sulfonylurea use were associated with greater hip BMD loss.”

    Humansin men with type 2 diabeteshipmales

    More Rapid Bone Mineral Density Loss in Older Men With Diabetes: The Osteoporotic Fractures in Men (MrOS) Study

    The Journal of clinical endocrinology and metabolism

More on Bone mineral density

mvAge

downin humans1

1 study
  1. Thiazolidinediones are linked with lower mvAge in humans (genetically proxied, drug-target Mendelian randomization) (P value = 3.50 × 10−10).

    “Similarly, genetically proxied thiazolidinediones (P value = 3.50 × 10−10)”

    Humansgenetically proxied, drug-target Mendelian randomization

    Multivariate genome-wide analysis of aging-related traits identifies novel loci and new drug targets for healthy aging

    Nature aging

More on mvAge

Ferroptosis

downin reviews1

1 study
  1. Thiazolidinediones decrease ferroptosis (preclinical models of Alzheimer's disease).

    “TZDs ameliorated neuroinflammation and ferroptosis in preclinical models of AD.”

    Reviewpreclinical models of Alzheimer's disease

    Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis

    Journal of Alzheimer's disease : JAD

More on Ferroptosis

Glycemic control

upin humans1

1 study
  1. Thiazolidinediones improve glycemic control in humans.

    “Thiazolidine derivatives and metformin are effective for glycemic control”

    Review

    Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome

    Geriatrics & gerontology international

Egg-laying rate

upin worms1

1 study
  1. Thiazolidinediones improve egg-laying rate in worms (high glucose).

    “Antidiabetic drugs of the biguanide and thiazolidine classes ameliorated the detrimental effect of glucose on egg-laying rate”

    Model organismshigh glucose

    Glucose-induced abnormal egg-laying rate in Caenorhabditis elegans

    Bioscience, biotechnology, and biochemistry

What is thiazolidinediones linked with?

15

Studies link thiazolidinediones with 15 measures, among them bone fracture, dementia and autoimmune rheumatic disease.

Bone fracture

upin humans3upin reviews1HR 1.22

4 studies
  1. Thiazolidinediones predict bone fracture in humans (type 2 diabetes and overweight or obesity) (HR 1.22; 95% CI, 1.02-1.46).

    “Thiazolidinedione use (hazard ratio [HR] 1.22; 95% CI, 1.02-1.46) and insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”

    Human trialtype 2 diabetes and overweight or obesity

    Predictors of Fracture in Middle-Aged and Older Adults With Type 2 Diabetes and Overweight or Obesity

    The Journal of clinical endocrinology and metabolism

  2. Thiazolidinediones raise the risk of bone fracture.

    “thiazolidinediones, sulfonylurea and some insulin regimens increase fracture risk”

    Review

    Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review

    Journal of bone metabolism

  3. Thiazolidinediones are associated with bone fracture in humans.

    “Thiazolidinediones (TZDs) were linked with increased fracture risk”

    Review

    Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies

    Diabetology & metabolic syndrome

  4. Thiazolidinediones raise the risk of bone fracture in patients with diabetes mellitus.

    “Some studies suggest that TZDs may have negative impact on bone health by decreasing bone formation and increasing the fracture risk.”

    Reviewin patients with diabetes mellitus

    The effect of antidiabetic drugs on bone metabolism: a concise review

    Endocrine

More on Bone fracture

Dementia

downin humans4RR 0.78

4 studies
  1. Thiazolidinediones are linked with a lower risk of dementia in humans (network meta-analysis of observational studies, compared with non-users) (OR 0.68 (95% CI 0.57 to 0.81)).

    “thiazolidinedione (TZD) (OR = 0.68, 95%CI, 0.57 to 0.81)”

    Humansnetwork meta-analysis of observational studies, compared with non-users

    Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials

    Alzheimer's research & therapy

  2. Thiazolidinediones are linked with a lower risk of dementia in humans (people with diabetes, pooled cohort and case-control studies).

    “Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with significant reduction in risk of dementia.”

    Humanspeople with diabetes, pooled cohort and case-control studiesn = 3,046,661

    Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis

    Diabetes, obesity & metabolism

  3. Thiazolidinediones are linked with a lower risk of dementia in humans (compared with metformin monotherapy) (22% lower risk; HR 0.78, 95% CI 0.75 to 0.81).

    “After at least 1 year of treatment, TZD monotherapy was associated with a 22% lower risk of all-cause dementia onset (HR 0.78, 95% CI 0.75 to 0.81)”

    Humanscompared with metformin monotherapyat least 1 year of treatment

    Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes

    BMJ open diabetes research & care

  4. Thiazolidinediones lower the risk of dementia in longitudinal studies of people with diabetes (RR 0.78 [0.76, 0.81]).

    “Meta‐analysis of 7 longitudinal studies showed glitazones ( n = 1,081,519, RR=0.78[0.76,0.81], I 2 =0%) were associated with reduced dementia risk.”

    Reviewin longitudinal studies of people with diabetes

    Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: a systematic review and meta‐analysis

    AAIC 2025 abstract

More on Dementia

Autoimmune rheumatic disease

downin humans1

1 study
  1. Thiazolidinediones are associated with autoimmune rheumatic disease in humans (Type 2 diabetes; first add-on to metformin; compared with DPP-4 inhibitors) (aHR 0.65, 95% CI 0.42–1.01).

    “1.11 (95% CI, 0.94–1.29) for sulfonylureas and 0.65 (95% CI, 0.42–1.01) for thiazolidinediones.”

    HumansType 2 diabetes; first add-on to metformin; compared with DPP-4 inhibitors

    Comparative Risk of Incident Autoimmune Diseases by First Add-on Antidiabetic Drug Class After Metformin: A Population-Based Active-Comparator, New-User Cohort Study

    Research SquarePreprint

More on Autoimmune rheumatic disease

Aortic aneurysm

downin humans1

1 study
  1. Thiazolidinediones are associated with aortic aneurysm in humans (type 2 diabetes mellitus) (aHR 0.71, 95% CI 0.65–0.77).

    “thiazolidinediones (aHR 0.71, 95% CI 0.65 - 0.77)”

    Humanstype 2 diabetes mellitus8.5 ± 4.7 years52.8% mensn = 3,295,564

    Associations between Antidiabetic Drug Classes and Aortic Aneurysm Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study

    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

More on Aortic aneurysm

Pancreatic cancer

upin humans1HR 1.3

1 study
  1. Thiazolidinediones are linked with a higher risk of pancreatic cancer in humans (compared with GLP-1 RA users, propensity score-matched) (HR 1.30, 95% CI 1.001–1.678; absolute risk difference 0.15 percentage points).

    “thiazolidinediones (HR 1.30, 95% CI 1.001, 1.678; ARD 0.15% points)”

    Humanscompared with GLP-1 RA users, propensity score-matched

    Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network

    Journal of gastrointestinal cancer

More on Pancreatic cancer

Mortality

downin humans1HR 0.838

1 study
  1. Thiazolidinediones are linked with a lower risk of mortality in humans (HR 0.838, 95% CI 0.793-0.885).

    “metformin and thiazolidinedione (TZD) exposure were associated with lower mortality (HR 0.828, 95% CI 0.799-0.857 and HR 0.838, 95% CI 0.793-0.885, respectively)”

    Humansafter adjustment for demographics, comorbid conditions, renal function, and hemoglobin A1c; veterans with pulmonary hypertension and diabetes

    Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes

    Pulmonary circulation

Chronic respiratory disease

downin humans1OR 0.79

1 study
  1. Thiazolidinediones lower the risk of chronic respiratory disease in type 2 diabetes (OR 0.79, 0.69-0.91).

    “Thiazolidinediones reduced incident CRD by 21% (odds ratio (OR) 0.79, 0.69-0.91)”

    Reviewin type 2 diabetesn = 939,064

    Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis

    Therapeutic advances in endocrinology and metabolism

More on Chronic respiratory disease

Cognitive function

upin humans1

1 study
  1. Thiazolidinediones are associated with cognitive function in type 2 diabetes mellitus.

    “GLP-1 agonists, SGLT-2 inhibitors, and glitazones have a more robust association with a possible cognitive benefit”

    Reviewin type 2 diabetes mellitus

    Antidiabetic agents and risk of dementia in type 2 diabetes

    Asclepius International Journal of Scientific Health Science

Atrial fibrillation

upin humans1

1 study
  1. Thiazolidinediones are linked with a higher risk of atrial fibrillation in humans (type 2 diabetes, compared with SGLT2 inhibitors) (SHR 1.22, 95% CI 1.09-1.36).

    “Compared with SGLT2 inhibitors, the risk of AF was significantly higher in patients using thiazolidinediones (subdistribution hazard ratio [SHR], 1.22; 95% confidence interval [CI], 1.09-1.36)”

    Humanstype 2 diabetes, compared with SGLT2 inhibitorsmean follow-up of 6.2 yearsn = 36,744

    Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study

    Cardiovascular diabetology

More on Atrial fibrillation

Osteoporosis

upin humans1HR 1.39

1 study
  1. Thiazolidinediones are linked with a higher risk of osteoporosis in humans (multivariate Cox regression; compared with metformin) (HR 1.39 (1.01–1.92)).

    “For Diabetes-related risk factors, dipeptidyl peptidase-4 inhibitors (DPP4-inhibitors), insulin, and thiazolidinediones were associated with a higher risk of osteoporosis; HR were 1.36 (1.05–1.75), 1.32 (1.05–1.65), and 1.39 (1.01–1.92), respectively.”

    Humansmultivariate Cox regression; compared with metforminn = 25,635

    Incidence and risk factors for osteoporosis in people with type 2 diabetes mellitus in Thailand

    BMC endocrine disorders

More on Osteoporosis

All 15

Has thiazolidinediones been tested in people?

0 of 2 about aging

Yes: 1 trial and 43 observational studies in people have been published, and 2 trials are registered.

In trials

Trial sponsors

  • Sanofi

    Company1 trialPhase 4112 people

Latest

Dec 2025: 1Jan 2026: 5Feb 2026: 8Mar 2026: 6Apr 2026: 3May 2026: 3Jun 2026: 5Jul 2026: 1Aug 2026: 1Sep 2026: 6Oct 2026: 12Nov 2026: 556 papers in 12 months

See all 119 papers on thiazolidinediones